Galapagos has gained a €4.4 million equity investment from GlaxoSmithKline as the two companies expand an alliance on osteoarthritis. GSK will bring a drug discovery program against a selected GSK target into the alliance. Within this additional program, Galapagos will progress a disease-modifying drug toward completion of clinical Phase IIa, at which point GSK's global research and development organization will be responsible for the late-stage development, production and marketing of the drug. Release | Report